1. Hong Kong Stocks

  2. •

    Consumer durables

  3. •

    Other consumer specialties
Baijin Life Science Holdings Limited

Baijin Life Science Holdings Limited

1.63
HKD
-0.06
(-3.85%)
550.03MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1.92
1.93
1.48
1.26
1.06
0.96
0.59
0.17
0.18
0.14
0.08
0.2
0.11
- -
Basic EPS, GAAP
0.21
0.07
-0.08
-0.14
-0.73
-0.24
-1.48
-0.21
-0.04
0.01
-0.01
- -
-0.04
- -
Free Cash Flow per Basic Share
0.14
-0.12
-0.15
-0.61
0.46
-0.13
-0.01
-0.07
- -
-0.04
-0.01
-0.05
-0.03
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.85
1.91
1.87
1.73
1.33
1.11
0.44
0.16
0.11
0.12
0.14
0.18
0.2
0.2
Tangible Book Value per Share
2.85
1.91
1.87
1.73
1.33
1.11
0.44
0.16
0.11
0.12
0.06
0.14
0.18
0.18
Basic Weighted Avg Shares
140
140
142
168
177
178
191
249
355
603
645
694
843
806
Sales/Revenue/Turnover
268
271
210
212
187
171
112
43
63
87
54
136
89
- -
Operating Margin (%)
11.34
5.81
-9.1
-10.97
-12.64
-19.92
-37.29
-99.4
-16.52
12.66
-18.74
4.59
-53.03
- -
Depreciation Expense
6
6
4
2
2
2
4
2
1
1
2
7
10
- -
Net Income, GAAP
30
10
-11
-24
-130
-43
-282
-52
-15
9
-7
- -
-38
- -
Effective Tax Rate (%)
7.58
37.34
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
11.02
3.71
-5.21
-11.25
-69.27
-25
-251.68
-119.53
-24.68
9.99
-13.88
-0.23
-42.4
- -
Working Capital
310
170
304
272
141
53
75
44
34
78
80
177
127
127
LT Debt
- -
- -
- -
- -
- -
- -
6
- -
1
- -
41
82
6
6
Total Equity
399
268
314
290
237
198
85
46
36
78
113
156
192
192
Return on Invested Capital (%)
- -
2.79
- -
- -
- -
- -
- -
- -
- -
16.03
- -
- -
- -
- -
Return on Capital (%)
- -
2.81
- -
- -
- -
- -
- -
- -
- -
13.05
- -
- -
- -
- -
Return on Common Equity (%)
- -
3.02
-3.76
-7.91
-49.29
-19.71
-199.09
-79.01
-37.8
15.2
-8.53
-0.27
-23.34
- -

Capital Structure

HKD

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
18
16
23
LT Borrowings
75
62
- -
LT Finance Leases
7
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
772
772
932
Market Capitalization
533
433
550

Working Capital

HKD

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
227
221
192
Cash, Cash Equivalents & STI
48
57
43
Accounts Receivable, Net
25
19
15
Inventories
71
70
58
Total Current Liabilities
50
53
65
Payables & Accruals
- -
- -
- -
ST Debt
18
16
23
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.66%
40.39%
23.34%
Free Cash Flow
-79.37%
-387.37%
-31.07%
Net Income, GAAP
1,234.67%
2,275.07%
11,883.23%
Sales/Revenue/Turnover
4.83%
32.7%
-34.12%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
54
2025
- -
- -
136
2026
- -
- -
89

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
- -
2026
- -
- -
-0.04

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sze Ming Cheung
Full Time Employees
84
Sector
Consumer durables
Industry
Other consumer specialties
Address
Office B, Pico Tower Hong Kong Hong Kong
IPO Date
Oct 17, 2014
Website
affluent-partners.com
Similar Companies
Titan Company Limited (NSE:TITAN)
PC Jeweller Ltd. (NSE:PCJEWELLER)
Sky Gold and Diamonds Limited (NSE:SKYGOLD)
Shanti Gold International Limited (NSE:SHANTIGOLD)
Tribhovandas Bhimji Zaveri Limited (NSE:TBZ)
Deepa Jewellers Limited (NSE:DEEPA)
Business
Baijin Life Science Holdings Limited Baijin Life Science Holdings Limited (1466.HK ), an investment holding company incorporated in 2014 and headquartered in Wan Chai, Hong Kong, engages in the purchase, processing, design, production, and wholesale distribution of pearls and jewelry products, including precious stones, metals, costume jewelry, watches, clocks, and silverware. The company operates through five primary segments: Sales of Pearls and Jewellery Products, involving the design, production, and sale of pearls and fine jewelry on an ODM and OEM basis; Skincare Solutions, offering products under the FO brand name to cosmetics stores, hospitals via sales contracts, and individuals through online platforms; Research and Development Services, providing scientific, pharmaceutical, cellular drugs, large molecule drugs, and clinical research services; Brand Marketing and Consulting Services, delivering contract-based marketing and consultation; and Strategic Investment and Financial Services, focusing on real estate financial assets investments. It serves luxury goods, life sciences, and skincare markets, targeting wholesale distributors, retailers, cosmetics outlets, hospitals, online consumers, and investment counterparties, with geographic operations spanning Hong Kong, the People's Republic of China, the United States, Europe, Asia, the United Kingdom, and Japan. In a significant strategic shift, the company, formerly known as Affluent Partners Holdings Limited, underwent a rebranding to Baijin Life Science Holdings Limited in January 2025 to align with its evolving focus on life sciences alongside its jewelry heritage, effective early that year without impacting shareholder rights. This name change reflects a pivot toward expanded R&D in cellular technology-based services, skincare brand development, and diversified operations beyond traditional pearls and jewelry. Recent financial developments include a positive profit alert for the six months ending September 30, 2025, anticipating a net profit of approximately HK$2.5 million versus a prior loss, alongside revenue growth reported in annual results despite a minor loss; however, it recognized a HK$20 million goodwill impairment tied to the acquisition of Tonnett Julis Holdings Limited, and applied to resume share trading on July 28, 2025, with its 2025 AGM scheduled for September 30, 2025.